CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows:

• Boston BD Biotech Conference on April 2-3, 2013, at the Four Seasons Hotel in Boston, MA
• Xconomy Forum: Boston Biotech Seizes the Momentum on April 4, 2013, at Biogen Idec Building 8 in Cambridge, MA
• BioCentury Future Leaders in the Biotech Industry Conference on April 5, 2013, at 1:30pm ET in room 402/403 at the Millennium Hotel in New York, NY. A breakout session will be held immediately following the presentation in room 401

A webcast of the Future Leaders conference presentation can be accessed by visiting the investors section of the Company’s website at www.verastem.com. A replay of the webcast will be archived on the Verastem website for two weeks following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Investor contact:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com
or
Media contact:
For Verastem, Inc.
Kari Watson, 781-235-3060
kwatson@macbiocom.com